October 2007
BioWorld Today;10/31/2007, Vol. 18 Issue 212, p6
This section offers news briefs on U.S. patents awarded to the biotechnology industry. Nventa Biopharmaceuticals Corp. received a patent that covers compositions and methods for inducing or enhancing immune responses to a human papillomavirus antigen. Penwest Pharmaceuticals Co. obtained a patent titled "Sustained Release Formulations of Oxymorphone." The patent issued to Protox Therapeutics Inc. covers the composition of PRX302, the company's drug candidate from its PORxin technology platform and its use in prostate cancer.


Related Articles

  • NVENTA UNVEILS IMMUNOLOGICAL DATA FROM HSPE7 PHASE 1 TRIAL.  // Worldwide Biotech;May2008, Vol. 20 Issue 5, p1 

    The article reports on the release of interim immunological data from the first two cohorts of Nventa Biopharmaceuticals Corporation's ongoing Phase 1 clinical trial of its lead product candidate, HspE7. The product is being tested in patients with cervical intraepithelial neoplasia (CIN). It...

  • U. S. PATENT DISCLOSURES.  // BioWorld Today;3/9/2007, Vol. 18 Issue 47, p8 

    The article offers update on patent disclosures in the U.S. Inovio Biomedical Corp. subsidiary Genetronics Inc., was issued a patent for a method of delivering biological material. Meanwhile, Lpath Inc. received a patent entitled Compositions and Methods for the Treatment and Prevention of...

  • U.S. PATENT DISCLOSURES.  // BioWorld Today;5/31/2007, Vol. 18 Issue 105, p5 

    The article offers news briefs related to patent disclosures for drugs. A patent for the use of HspE7 therapeutic vaccine for human papillomavirus (HPV)-related diseases was received by Nventa Biopharmaceuticals Corp. A patent for a method of extracting viruses from cell culture was granted to...

  • CLINIC ROUNDUP.  // BioWorld Today;3/27/2008, Vol. 19 Issue 60, p2 

    This section offers news briefs related to the biotechnology industry. Metabolex Inc. announced that it has dosed the first cohort of healthy subjects in a Phase I clinical trial of MBX-2982, a potential treatment for Type II diabetes. Nventa Biopharmaceuticals Corp. revealed interim...

  • Company Strategy.  // PharmaWatch: Biotechnology;May2009, Vol. 8 Issue 5, p18 

    The article offers world news briefs related to company strategy of biotechnology industry. An arrangement agreement was signed by Akela Pharma Inc. and Nventa Biopharmaceuticals Corp. to combine the two companies. The $16 per share offer made by Astellas Pharma Inc. for CV Therapeutics Inc....

  • U.S. Patent Awarded for Rochester's Pioneering HPV Vaccine Work.  // Biomedical Market Newsletter;11/30/2011, Vol. 21, p336 

    The article discusses the award of a patent to three Rochester University based virologists Robert Rose, Richard Reichman, and William Bonnez for the creation of virus-like particles (VLPs) that mimic Human papillomavirus 16 (HPV 16). The team of virologist is the first to show that HPV...

  • Economic Hard Times Catch up to Nventa; Cuts Staff 60 Percent. Young, Donna // BioWorld Today;10/10/2008, Vol. 19 Issue 198, p1 

    The article discusses the cutting of workforce by Nventa Biopharmaceuticals Corp. by 60 percent, from 13 employees to five. The company is seeking merger and acquisition opportunities to strengten its pipeline and finances. Nventa has been trying to raise cash fo fund Phase II trials of HspE7,...

  • Bivalent HPV may offer longer duration of protection. Blazek, Nicole // Infectious Disease News;Dec2009, Vol. 22 Issue 12, p20 

    The article discusses research on the long-term immune response protection in patients who were given the bivalent human papillomavirus (HPV) vaccine, presented by Mark H. Einstein at the 47th Annual Meeting of the Infectious Diseases Society of America, held from October 29 to November 1, 2009.

  • US patent awarded for Rochester's pioneering HPV vaccine work.  // Biomedical Market Newsletter;11/30/2011, Vol. 21, p320 

    The article reports on the U.S. patent award awarded to three virologists from the University of Rochester, Rochester, New York for their pioneering research in the field of human papillomavirus vaccines (HPV). The virologist team comprising of Richard Reichman, William Bonnez, and Robert Rose...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics